The pharmaceutical industry has always been a "fertile land" for innovative research and development

[China Pharmaceutical network industry trends] by the end of 2017, the number of Chinese pharmaceutical manufacturing enterprises increased by 248 over the same period of last year, reaching 7697 Throughout 2012-2017, the number of pharmaceutical enterprises in China has been increasing continuously, with 1622 increasing in total in six years, with a very rapid growth The pharmaceutical industry is developing rapidly, and some analysts point out that the pharmaceutical industry has always been a "fertile ground" for innovative research and development In recent years, China has been giving policy support to pharmaceutical innovation and development, hoping to further guide pharmaceutical enterprises to increase R & D investment and support the overall innovation of the industry "Companies with corresponding technology reserves and rich new drug layout will usher in development opportunities, and are also expected to form a long-term good for pharmaceutical enterprises that carry out cro business The investment opportunities of relevant themes in the A-share market are also worthy of attention." Some insiders said I have learned that in recent years, many local governments have issued policies to support the development of pharmaceutical innovation Guangzhou has issued plans to promote the innovation and development of biomedical industry Recently, Guangzhou Municipal Commission of science and technology innovation issued the action plan for innovation and development of Guangzhou biomedical industry, which requires that we should vigorously promote the construction and development of five key idea industries, about 10 leading enterprises in the industry, 10 high growth enterprises on the left and right, and five key common industry support platforms, and vigorously support a number of key technology and major product innovation Key sub industries guide the establishment of more than 5 professional venture capital funds (referred to as "511515 project") to promote the development of Guangzhou biomedical industry into value chain and innovation chain Jiangsu released policy dividend to encourage innovation and development of pharmaceutical industry Recently, Jiangsu has issued the implementation opinions on deepening the reform of the review and approval system and encouraging the innovation of pharmaceutical medical devices (hereinafter referred to as the implementation opinions on the innovation of pharmaceutical devices) and the implementation opinions on the reform and improvement of the supply guarantee and use policy of generic drugs (hereinafter referred to as the implementation opinions on the supply guarantee and use policy of generic drugs) to encourage the innovation of pharmaceutical medical devices In terms of high quality of generic drugs and improving the supply guarantee of generic drugs, the detailed implementation opinions were made clear, and the policy dividend was released The opinions on the implementation of medical device innovation encourages innovation, proposes to support the qualified biomedical enterprises to apply for high-tech enterprises, increase the implementation of R & D expenses plus deduction and high-tech enterprise income tax preferential policies, increase the support for pharmaceutical industry cluster areas and key pharmaceutical parks, and give priority to the implementation of national reform policies in the park We should pay equal attention to encouraging innovation, promoting drug imitation and reducing the burden of drug use As a special commodity, medicine is directly related to people's health and life safety In view of the major diseases seriously endangering the health of Chinese people, in 2008, China launched the national science and technology major special project for major new drug creation (hereinafter referred to as the new drug creation project), developed drugs with good efficacy, small side effects and reasonable price, and promoted the leapfrog development of China's pharmaceutical industry from imitation based to independent innovation based After nearly 10 years of efforts, China 's national strategic drug independent guarantee capacity has realized the transformation from scratch In order to promote the innovation and development of the pharmaceutical industry, the domestic investment in pharmaceutical research and development and industrial investment has grown rapidly In 2015, the R & D cost of Enterprises above the industry scale was about 45 billion yuan, with a compound growth of more than 30% in the past 10 years The output value and profit added value of the pharmaceutical industry maintain double-digit growth, ranking the forefront of all industries With the strong support of policies, a number of innovative backbone enterprises have significantly improved their R & D capabilities, such as Jiangsu Hengrui transforming from a single chemical drug variety manufacturer to a multi variety R & D and production innovative pharmaceutical enterprise covering chemical and biological drugs; Zhejiang Haizheng transforming from a API factory to a large biological pharmaceutical group In the future, for the development of innovative drugs, China will further develop a series of guiding policies, further quantitative evaluation system, and comprehensively improve the innovation ability and international competitiveness of China's pharmaceutical industry.